Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07446322) titled 'FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Oncolytics Biotech
Condition:
Ras-mutated Metastatic Colorectal Cancer
mCRC
MSS Metastatic Colorectal Cancer
Intervention:
Drug: Bevacizumab
Drug: FOLFIRI
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 30, 2026
Target Sample Size: 60
Cou...